Diomed takes EVLT (EndoVenous Laser Treatment) to broader US market:
This article was originally published in Clinica
Executive Summary
Diomed Holdings has received US 510(k) clearance to expand the market for its EndoVenous Laser Treatment (EVLT). Since January 2002, the EVLT has been sold for treating venous reflux in the great saphenous vein associated with varicose veins. The new clearance allows the firm's 810nm D15 Plus and D30 Plus laser systems and associated procedure kits to be used for treatment of venous incompetence and for reflux of other superficial veins in the lower extremity. Describing the clearance as a first"s, James Wyli, Diomed's president and CEO, said: "We view this as a further growth opportunity." Lower extremity venous insufficiency affects 20-25% of women and 10-15% of men, said the Andover, Massachusetts firm.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.